StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$8.66M
P/E ratio
0.0
Price to sales
–
Price to book
0.03
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
$249.30M
EPS, diluted
$0.59
Book value per share
$0.57
Diluted shares
468M

Trading

Previous close
$0.02
Open
$0.02
Day's range
$0.02 – $0.02
Volume
204,601
Average volume (20 days)
480,199

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodOTLCS&P 500DifferenceOTLC per yearS&P 500 per year
1 month-20.9%+0.6%−21.6 pts
3 months-54.9%+3.4%−58.3 pts
Year to date-76.4%+13.3%−89.7 pts
1 year-81.4%+16.6%−98.0 pts
3 years-53.8%+86.4%−140.1 pts-22.7%+23.1%
5 years-85.8%+81.9%−167.6 pts-32.3%+12.7%
10 years-96.5%+318.9%−415.4 pts-28.5%+15.4%

Fifteen years at a glance

Fiscal years 2011 to 2025, USD

Revenue

–

Operating income

-$3.19M

Net income

$249.30M

EPS, diluted

$0.59

Free cash flow

–
Reported period

Press releases

Releases Oncotelic Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Oncotelic Therapeutics

Pharmaceutical Preparations

Oncotelic Therapeutics, Inc. is a biopharmaceutical enterprise focused on researching, developing, and commercializing therapeutic treatments. The company concentrates its operational endeavors on pharmaceutical solutions designed to address oncologic indications and critical viral conditions. Its development initiatives feature innovative proprietary candidates, including targeted antisense oligodeoxynucleotide therapies addressing transforming growth factor-beta and specialized synthetic formulations intended for diverse clinical applications across medicine.

Company profile, executives and history

Oncotelic Therapeutics stock: common questions

What is Oncotelic Therapeutics's stock price?

OTLC closed at $0.02 on Oct 19, 2026, up 11.45% on the day.

What is Oncotelic Therapeutics's market cap?

Oncotelic Therapeutics was worth $8.66M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is OTLC's P/E ratio?

OTLC trades at 0.0 times earnings, based on diluted earnings per share of $0.59 over fiscal 2025.

Does Oncotelic Therapeutics pay a dividend?

No. Oncotelic Therapeutics has not paid a cash dividend over the last twelve months.

How has OTLC stock performed over the past year?

Including dividends, OTLC returned -81.4% over the past year, against +16.6% for the S&P 500.

Who are Oncotelic Therapeutics's competitors?

Companies most similar to Oncotelic Therapeutics by business, industry and size include APLM, MAIA, GERN, OCS, RARE.

See a number that looks wrong?